TNGX
Tango Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.8% ·
share flow +11.6% ·
net new positions +10.5%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 595.91K | $14.87M | n/a | n/a |
| Q2 2026 | 96 | +22 | 90.51M | $2.83B | +24 | −2 |
| Q1 2026 | 77 | 0 | 72.21M | $1.51B | +9 | −9 |
| Q4 2025 | 76 | 0 | 64.83M | $574.42M | +1 | −1 |
| Q3 2025 | 19 | +2 | 27.21M | $228.58M | +3 | −1 |
| Q2 2025 | 14 | 0 | 22.55M | $115.47M | +1 | −1 |
| Q1 2025 | 11 | +1 | 6.63M | $9.09M | +2 | −1 |
| Q4 2024 | 10 | 0 | 4.99M | $15.42M | +3 | −3 |
| Q3 2024 | 9 | -1 | 6.83M | $52.57M | +1 | −2 |
| Q2 2024 | 10 | n/a | 5.64M | $48.44M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 5.65M | +3.4% | $47.43M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | The Vanguard Group ✦ (passive) | 5.05M | +25.5% | $42.44M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | State Street Global Advisors ✦ (passive) | 3.37M | +143.4% | $28.27M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Point72 Asset Management ✦ | 2.92M | New | $24.52M | 0.1% | New | 1 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 2.51M | -57.5% | $21.09M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.88M | +6.4% | $15.82M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Goldman Sachs Group ✦ | 1.51M | n/a | $12.68M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 1.49M | -14.5% | $12.51M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 9 | Millennium Management ✦ | 1.30M | -26.9% | $10.88M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 430.38K | New | $3.62M | 0.0% | New | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 253.29K | New | $2.13M | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | Morgan Stanley ✦ | 251.79K | n/a | $2.12M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Fisher Asset Management ✦ | 210.35K | -6.1% | $1.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 144.43K | +550.1% | $1.21M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 79.17K | +0.3% | $665,069 | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 16 | JPMorgan Chase ✦ | 67.83K | n/a | $569,788 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 17 | Renaissance Technologies ✦ | 55.30K | -15.6% | $464,520 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 40.67K | +5.9% | $343,000 | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | Fidelity (FMR) ✦ | 6.43K | +15.2% | $53,978 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $24.52M | 0.1% |
| D. E. Shaw & Co. | $3.62M | 0.0% |
| Wellington Management | $2.13M | 0.0% |
Exited
| Citadel Advisors | $281,933 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 180.17M shares, $3.72B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 600 sh · $15,192
Officer · 26.40K sh · $645,604
Officer · 2.40K sh · $60,412
Officer · 700 sh · $15,962
Officer · 5.10K sh · $122,238
Officer · 27.00K sh · $603,909
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology